<DOC>
	<DOCNO>NCT00955292</DOCNO>
	<brief_summary>This phase 1 study quarfloxin ( CX-3543 ) design test safety , tolerability , high safe dose drug administer intravenously weekly three week four week cycle patient advance solid tumor .</brief_summary>
	<brief_title>Dose-escalation Study Quarfloxin Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Quarfloxin first-in-class small-molecule target cancer therapeutic derive validated fluoroquinolone class drug . Quarfloxin rationally design target G-quadruplex ( QPLX ) DNA structure disrupt protein-DNA interaction essential cancer cell . The QPLX target quarfloxin form within ribosomal DNA ( rDNA ) QPLX bound nucleolin protein .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients histologically confirm solid tumor lymphomas . Tumor progression receive standard/approved chemotherapy approve therapy . One tumor measurable radiograph CT scan , evaluable disease ( e.g. , malignant ascites ) . Karnofsky performance status great equal 70 . Life expectancy least 3 month . Age least 18 year . Patients must central IV access , agree insertion central IV line . Normal oxygen saturation pulse oximetry room air A negative pregnancy test ( female ) . Acceptable liver function evaluate laboratory result Acceptable renal function evaluate laboratory result Acceptable hematologic status evaluate laboratory result No clinically significant urinalysis abnormality Acceptable coagulation status evaluate laboratory result Fertile men woman must use effective contraceptive method study . Seizure disorder require anticonvulsant therapy . Known brain metastasis ( unless previously treat well controlled period great equal 3 month ) . Severe chronic obstructive pulmonary disease hypoxemia , uncorrectable pulmonary compromise . Major surgery , diagnostic surgery , within 4 week prior first dose test drug . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . Pregnant nursing woman . Treatment radiation therapy , surgery , chemotherapy , investigational therapy within one month prior study entry ( 6 week nitrosoureas Mitomycin C ) . Unwillingness inability comply procedure require protocol . Known infection HIV , hepatitis B , hepatitis C. Clinically significant bleeding event within last 3 month , unrelated trauma , underlying condition would expect result bleed diathesis . Patients currently receive investigational agent . Patients exhibit allergic reaction similar structural compound ( e.g. , fluoroquinolones , biological agent formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>G-Quadruplex</keyword>
</DOC>